Original title: The substrate envelope strategy: Structural basis for resistance mitigation in antiviral drug design
Qiaojie Xu, Jiwei Zhang, Yanxu Hou, Zhou Tan +5 · September 2026
Viruses quickly mutate to become resistant to medicines. To solve this, researchers reviewed a strategy called the substrate envelope hypothesisThe idea that a drug should only occupy the same space as the virus's natural molecule in the enzyme, nothing more.. Instead of making drugs that stick out, scientists design them to fit strictly inside the physical space used by the virus's own natural targets. Because the drug interacts only with essential parts of the viral enzyme, the virus cannot easily change those spots. If the virus mutates to push the drug away, it damages its own ability to process its natural materials. This creates a fatal fitness costWhen a mutation makes the virus less able to replicate or survive. for the virus. The authors found that this design method keeps drugs potent while blocking resistance across HIV, hepatitis C, influenza, and SARS-CoV-2, including both proteases and non-protease targets.
Imagine you have a lock that only a specific original key can open. You need to make a duplicate, so you copy that key exactly, shape for shape. If someone tries to change the lock so your duplicate stops working, they will also make the original key fail, ruining the lock. Here, the lock is a viral protein, the original key is its natural target molecule, and the duplicate key is the drug; any mutation that rejects the drug also breaks the virus.
Antiviral drugs often stop working because viruses mutate and escape them. This review describes a design principle that forces any mutation escaping the drug to also break the virus's own machinery, making resistance extremely costly. That could yield longer-lasting treatments for HIV, hepatitis C, influenza, and COVID-19.
The abstract doesn't state specific limitations; it presents a review of existing work and proposes extending the strategy to non-protease targets without discussing caveats. As a review, it relies on previously reported structures and does not introduce new experimental data.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
The substrate envelope strategy: Structural basis for resistance mitigation in antiviral drug design — Qiaojie Xu, Jiwei Zhang, Yanxu Hou et al. — Pharmaceutical science advances — doi:10.1016/j.pscia.2026.100147
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper.